BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

被引：0
|
作者：
Song, Erwei
Yao, Herui
Sun, Meili
Zong, Hong
Lin, Rongbo
Zou, Wen
Ding, Muran
Yu, Jing
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-04-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-04-03
引用
收藏
页数：3
相关论文
共 50 条
  • [21] POPULATION PHARMACOKINETIC ANALYSIS OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH HER2-POSITIVE BREAST CANCER OR OTHER SOLID TUMORS.
    Yin, O.
    Xiong, Y.
    Endo, S.
    Yoshihara, K.
    AbuTarif, M.
    Wada, R.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S48 - S48
  • [22] A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
    Li, Bob T.
    Pegram, Mark D.
    Lee, Keun-Wook
    Sharma, Manish
    Lee, Jeeyun
    Spira, Alexander I.
    Hanna, Glenn J.
    Kang, Yoon-Koo
    Rasco, Drew W.
    Moore, Kathleen N.
    Weinberg, Benjamin Adam
    Alonso, Michael N.
    Ptacek, Jason
    Yin, Ming
    Tapia, Coya
    Xu, Lu
    Perez, Edith A.
    Dumbrava, Ecaterina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
    Krop, Ian E.
    Masuda, Norikazu
    Mukohara, Toru
    Takahashi, Shunji
    Nakayama, Takahiro
    Inoue, Kenichi
    Iwata, Hiroji
    Toyama, Tatsuya
    Yamamoto, Yutaka
    Hansra, Damien Mikael
    Takahashi, Masato
    Osaki, Akihiko
    Koyama, Kumiko
    Inoue, Tatsuya
    Yonekura, Takatoshi
    Mostillo, Joseph
    Ohwada, Shoichi
    Tanaka, Yoshimi
    Sternberg, David W.
    Yonemori, Kan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Interim Results from a Phase 1b/2a Study of Trastuzumab Emtansine and Docetaxel, With and Without Pertuzumab, in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Martin, M.
    Garcia-Saenz, J. A.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Strasak, A.
    Patre, M.
    Branle, F.
    Fumoleau, P.
    CANCER RESEARCH, 2012, 72
  • [25] BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: afirst-in-human, open-label, multicentre, phase 1 study
    Ma, Yuxiang
    Huang, Yan
    Zhao, Yuanyuan
    Zhao, Shen
    Xue, Jinhui
    Yang, Yunpeng
    Fang, Wenfeng
    Guo, Ye
    Han, Yaqian
    Yang, Kunyu
    Li, Yongsheng
    Yang, Jun
    Fu, Zhenming
    Chen, Gang
    Chen, Likun
    Zhou, Ningning
    Zhou, Ting
    Zhang, Yaxiong
    Zhou, Huaqiang
    Liu, Qianwen
    Zhu, Yi
    Zhu, Hai
    Xiao, Sa
    Zhang, Li
    Zhao, Hongyun
    LANCET ONCOLOGY, 2024, 25 (07): : 901 - 911
  • [26] Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study
    Wang, Jiayu
    Liu, Yunjiang
    Zhang, Qingyuan
    Li, Wei
    Feng, Jifeng
    Wang, Xiaojia
    Fang, Jianmin
    Han, Yiqun
    Xu, Binghe
    CANCER COMMUNICATIONS, 2024, 44 (07) : 833 - 851
  • [27] A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
    Zhou, Chenfei
    Wang, Bin
    Teng, Christina
    Yang, Hui
    Piha-Paul, Sarina A.
    Richardson, Gary
    Malalasekera, Ashanya
    Sun, Yajun
    Wang, Wei
    Liu, Jieqiong
    Shi, Yan
    Zhan, Xianbao
    Lemech, Charlotte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [28] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 study
    Cortes, Javier
    Dieras, Veronique
    Lorenzen, Sylvie
    Montemurro, Filippo
    Riera-Knorrenschild, Jorge
    Thuss-Patience, Peter
    Allegrini, Giacomo
    De laurentiis, Michele
    Lichinitser, Mikhail
    Lohrisch, Caroline
    Perez-Garcia, Jose
    Ricci, Francesco
    Sakaeva, Dina
    Serpanchy, Rosanne
    Sufliarsky, Jozef
    Vidal, Maria
    Irahara, Natsumi
    Wohlfarth, Christine
    Aout, Mounir
    Gelmon, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [29] HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
    Lu, J.
    Budd, G. T.
    Frentzas, S.
    Park, H.
    Shannon, C.
    Rugo, H. S.
    O'Shaughnessy, J.
    Demichele, A.
    Tolaney, S. M.
    Eek, R. W.
    McCartney, A.
    Cuff, K.
    Esserman, L.
    Alika, A.
    Xu, D.
    Li, M.
    Le, T.
    L'Heureux, D. Z.
    Yan, J.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S223 - S223
  • [30] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
    Lewis, Gail D.
    Li, Guangmin
    Guo, Jun
    Yu, Shang-Fan
    Fields, Carter T.
    Lee, Genee
    Zhang, Donglu
    Dragovich, Peter S.
    Pillow, Thomas
    Wei, Binqing
    Sadowsky, Jack
    Leipold, Douglas
    Wilson, Tim
    Kamath, Amrita
    Mamounas, Michael
    Lee, M. Violet
    Saad, Ola
    Choeurng, Voleak
    Ungewickell, Alexander
    Monemi, Sharareh
    Crocker, Lisa
    Kalinsky, Kevin
    Modi, Shanu
    Jung, Kyung Hae
    Hamilton, Erika
    LoRusso, Patricia
    Krop, Ian
    Schutten, Melissa M.
    Commerford, Renee
    Sliwkowski, Mark X.
    Cho, Eunpi
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345